Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Average Price Target of $25.92

Posted by Stanley Muller on Oct 1st, 2026

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $25.92.

RLAY has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Relay Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. HC Wainwright raised their price objective on shares of Relay Therapeutics from $28.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Citigroup reaffirmed a “market outperform” rating on shares of Relay Therapeutics in a research note on Monday, August 10th. Canaccord Genuity Group initiated coverage on shares of Relay Therapeutics in a report on Thursday, July 16th. They set a “buy” rating and a $29.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Monday, July 6th.

Get Our Latest Analysis on RLAY

Insiders Place Their Bets

In related news, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of Relay Therapeutics stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the sale, the insider directly owned 21,904,963 shares of the company’s stock, valued at $424,956,282.20. The trade was a 21.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Sanjiv Patel sold 48,199 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total value of $943,736.42. Following the completion of the sale, the chief executive officer owned 615,898 shares of the company’s stock, valued at $12,059,282.84. This represents a 7.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,157,974 shares of company stock worth $119,420,157 over the last three months. Insiders own 5.04% of the company’s stock.

Hedge Funds Weigh In On Relay Therapeutics

Several institutional investors have recently modified their holdings of the stock. Tidal Investments LLC increased its stake in shares of Relay Therapeutics by 14.7% in the 2nd quarter. Tidal Investments LLC now owns 176,782 shares of the company’s stock valued at $3,308,000 after acquiring an additional 22,682 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Relay Therapeutics during the 2nd quarter worth approximately $74,000. Allianz Asset Management GmbH bought a new position in Relay Therapeutics during the 2nd quarter worth approximately $750,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Relay Therapeutics during the second quarter valued at approximately $784,000. Finally, Frazier Life Sciences Management L.P. acquired a new position in Relay Therapeutics during the second quarter valued at approximately $19,004,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Stock Down 1.7%

Shares of RLAY stock opened at $18.05 on Monday. The stock has a 50-day moving average price of $19.11 and a 200 day moving average price of $16.26. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of -11.50 and a beta of 1.69. Relay Therapeutics has a 12 month low of $5.16 and a 12 month high of $21.27.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. Sell-side analysts predict that Relay Therapeutics will post -1.61 earnings per share for the current fiscal year.

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for diseases driven by genetically defined targets, particularly in oncology. The company uses its proprietary Dynamo platform, which combines structural biology, computational modeling, machine learning and medicinal chemistry to study how proteins move and to identify potential drug-binding sites that may be difficult to address with conventional approaches.

Relay’s pipeline has included targeted cancer therapies such as RLY-2608, an investigational oral inhibitor designed to selectively target PI3K-alpha mutations, and RLY-4008 (lirafugratinib), an investigational FGFR2 inhibitor developed for cancers with specific FGFR2 alterations.